Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Ultragenyx Looks to Launch 6 New Products in Japan by 2028-End: CCO
October 17, 2024
- Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
- Teclistamab Shows Sustained Responses in Japanese MM Patients: J&J
October 16, 2024
- CarbGeM Ties Up with University of Zurich on Bacterial Persistence Research
October 16, 2024
- Enhertu Gets Conditional Nod for Lung Cancer in China
October 16, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Lilly CEO Touts Benefits of Early AD Drug Kisunla
October 15, 2024
- Asahi Kasei Offshoot to Develop Cancer Vaccine Using Proprietary DDS Base
October 11, 2024
- Ono Snags Worldwide Rights to LigaChem’s ADC Assets
October 11, 2024
- Incubation JV of Takeda, Astellas, SMBC Boots Up in Japan
October 11, 2024
- Opdivo Approved for 1st Line Bladder Cancer Use in Taiwan: Ono
October 11, 2024
- Meiji Rebuts Nursing Group’s Claim on Concerns over Kostaive
October 10, 2024
- Viatris to Discontinue 36 Products/22 APIs in Portfolio Overhaul
October 10, 2024
- Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
October 9, 2024
- Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect
October 9, 2024
- Eisai Eyes 2 Trillion Yen Sales Mark by FY2032 with Leqembi as Driver
October 9, 2024
- Eisai’s Gout Drug Urece Approved in Thailand
October 9, 2024
- Astellas, AviadoBio Sign Dementia Gene Therapy Deal
October 9, 2024
- Novartis Launches Another Recall of Comtan over Nitrosamine Impurities
October 9, 2024
- J-TEC to Launch Jacemin Cell Sheet for Vitiligo on Oct. 11
October 8, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…